• PDF / 172,211 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 30 Downloads / 178 Views

DOWNLOAD

REPORT

1173-5503/20/0864-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 17 Oct 2020 No. 864

1

Recommend Documents

Is population genomic screening for breast/ovarian cancer cost effective?

101 72 163KB

Lenvatinib cost effective in advanced liver cancer in Australia

172 41 163KB

Trastuzumab cost effective in early breast cancer

115 43 122KB

Preoperative lymphoscintigraphy cost effective in vulvar cancer

157 31 166KB

MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1

146 99 3MB

Capecitabine + irinotecan cost effective for colorectal cancer in China

154 88 163KB

Advanced post-mastectomy radiotherapy cost effective in US

136 104 182KB

Olaparib

152 10 166KB

Cost-Effective

168 109 57MB

Prognostic Nutrition Index and Its Significance in Advanced Ovarian Cancer

171 49 226KB

Correction to: Outcome quality standards in advanced ovarian cancer surgery

183 92 191KB

Outcome quality standards in advanced ovarian cancer surgery

147 97 756KB